Publication Name	World Journal of Ophthalmology
Manuscript ID	15637
Country

Received	2014-12-01 08:25
Peer-Review Started	2014-12-02 14:52
To Make the First Decision	2015-02-07 14:52
Return for Revision	2015-02-10 13:52
Revised	2015-03-05 05:30
Second Decision	2015-05-15 16:28
Accepted by Journal Editor-in-Chief	2015-05-17 04:57
Accepted by Company Editor-in-Chief	2015-05-28 18:15
Articles in Press	2015-05-28 18:15
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-07-08 07:01
Typeset the Manuscript	2015-07-18 14:17
Publish the Manuscript Online	2015-08-17 11:09

ISSN	2218-6239 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Ophthalmology
Manuscript Type	Minireviews
Article Title	Diabetic macular edema: Efficacy and safety of anti-vascular endothelial growth factor therapy
Manuscript Source	Invited Manuscript
All Author List	Emre Güler and Ramazan Yağcı
Funding Agency and Grant Number
Corresponding Author	Ramazan Yağcı, MD, Department of Ophthalmology, Pamukkale University, Medical School, Çamlaraltı Mahallesi, 20160 Denizli, Turkey. ramazanyagci@yahoo.com
Key Words	Anti-vascular endothelial growth factor; Aflibercept; Bevacizumab; Diabetic macular edema; Pegabtanib; Ranibizumab
Core Tip	Diabetic retinopathy is one of the prominent reasons of vision loss in the industrial countries. Among these patients, diabetic macular edema (DME) is the main reason of vision impairment. Previous studies have shown that vascular endothelial growth factor (VEGF) has a major role in the pathogenesis of diabetic retinopathy and DME, as well as demonstrated favorable results for DME treatment. This review summarizes the outcomes of clinical trials that evaluated anti-VEGF agents including pegaptanib, ranibizumab, bevacizumab, and aflibercept in DME treatment.
Publish Date	2015-08-17 11:09
Citation	Güler E, Yağcı R. Diabetic macular edema: Efficacy and safety of anti-vascular endothelial growth factor therapy. World J Ophthalmol 2015; 5(3): 133-141
URL	http://www.wjgnet.com/2218-6239/full/v5/i3/133.htm
DOI	http://dx.doi.org/10.5318/wjo.v5.i3.133

Full Article (PDF)	WJO-5-133.pdf
Full Article (Word)	WJO-5-133.doc
Manuscript File	15637-Review.doc
Answering Reviewers	15637-Answering reviewers.pdf
Audio Core Tip	15637-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	15637-Conflict-of-interest statement.pdf
Copyright License Agreement	15637-Copyright assignment.pdf
Peer-review Report	15637-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	15637-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	15637-Scientific misconduct check.pdf
Scientific Editor Work List	15637-Scientific editor work list.pdf